P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT

por Baranwal, A., Mangaonkar, A., Shah, M., Litzow, M., Hogan, W., Patnaik, M., Alkhateeb, H.
Publicado 2022

Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set

por Goyal, G, Bartley, A C, Patnaik, M M, Litzow, M R, Al-Kali, A, Go, R S
Publicado 2017

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia

por Kenderian, S S, Al-Kali, A, Gangat, N, Letendre, L, Hogan, W J, Litzow, M R, Patnaik, M M
Publicado 2013

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment

por Gangat, N, Patnaik, M M, Begna, K, Al-Kali, A, Litzow, M R, Ketterling, R P, Hanson, C A, Pardanani, A D, Tefferi, A
Publicado 2016

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

por Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A
Publicado 2013

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

por Topp, M S, Stelljes, M, Zugmaier, G, Barnette, P, Heffner, L T, Trippett, T, Duell, J, Bargou, R C, Holland, C, Benjamin, J E, Klinger, M, Litzow, M R
Publicado 2018

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

por Haddox, C L, Mangaonkar, A A, Chen, D, Shi, M, He, R, Oliveira, J L, Litzow, M R, Al-Kali, A, Hogan, W J, Elliott, M A
Publicado 2017

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

por Pardanani, A, Abdelrahman, R A, Finke, C, Lasho, T T, Begna, K H, Al-Kali, A, Hogan, W J, Litzow, M R, Hanson, C A, Ketterling, R P, Tefferi, A
Publicado 2015

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

por Saeed, L, Patnaik, M M, Begna, K H, Al-Kali, A, Litzow, M R, Hanson, C A, Ketterling, R P, Porrata, L F, Pardanani, A, Gangat, N, Tefferi, A
Publicado 2017

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before...

por Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R
Publicado 2010

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention

por Sinha, S, Gastineau, D, Micallef, I, Hogan, W, Ansell, S, Buadi, F, Dingli, D, Dispenzieri, A, Gertz, M, Greiner, C, Hayman, S, Inwards, D, Johnston, P, Lacy, M, Litzow, M, Porrata, L, Winters, JL., Kumar, S
Publicado 2010

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

por Begna, K. H., Kittur, J., Gangat, N., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Pardanani, A., Hanson, C. A., Ketterling, R. P., Tefferi, A.
Publicado 2022

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

por Begna, K. H., Xu, X., Gangat, N., Alkhateeb, H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj-Spinner, A. P., Mangaonkar, A., He, R., Pardanani, A., Shah, M., Ketterling, R. P., Tefferi, A.
Publicado 2022